Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL

This study is testing an experimental CAR-T cell therapy called MB-CART19.1 in patients with aggressive non-Hodgkin lymphoma (a type of blood cancer) whose cancer has come back or stopped responding to standard treatments. CAR-T therapy involves engineering a patient's own immune cells to attack cancer. **You may be eligible if...** - You have an aggressive form of non-Hodgkin lymphoma - Your cancer came back after at least one standard chemotherapy and one additional treatment, OR you are ineligible for a stem cell transplant, OR your cancer returned after a prior stem cell transplant - Your lymphoma tests positive for the CD19 protein - You are otherwise healthy enough to undergo the treatment **You may NOT be eligible if...** - You have an isolated central nervous system lymphoma - Your cancer does not express CD19 - You have significant organ failure - You have an active autoimmune condition requiring immunosuppressive therapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.